Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Raubitschek

Showing results (81-90 of 89) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 89 results.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 29, 1998
Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patientsJ Y Wong, D Z Chu, D Yamauchi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 16, 1998
Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonal antibodyJ Y Wong, G E Thomas, D Yamauchi, et al.
Bioconjugate Chemistry|March 15, 2011
Site-specific conjugation of monodispersed DOTA-PEGn to a thiolated diabody reveals the effect of increasing peg size on kidney clearance and tumor uptake with improved 64-copper PET imagingLin Li, Desiree Crow, Fabio Turatti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 7, 2004
Pilot trial evaluating an 123I-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancerJeffrey Y C Wong, David Z Chu, Lawrence E Williams, et al.
Cancer Research|July 5, 2005
Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imagingTove Olafsen, Vania E Kenanova, Gobalakrishnan Sundaresan, et al.
European Journal of Nuclear Medicine|August 22, 2000
Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphomaG A Wiseman, C A White, M Stabin, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 6, 2000
High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragmentA M Wu, P J Yazaki, S w Tsai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2003
A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancerJeffrey Y C Wong, Stephen Shibata, Lawrence E Williams, et al.
Cancer Research|February 8, 2005
Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragmentsVania Kenanova, Tove Olafsen, Desiree M Crow, et al.
Pageof 9

Showing results (81-90 of 89) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 89 results.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 29, 1998
Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patientsJ Y Wong, D Z Chu, D Yamauchi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 16, 1998
Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonal antibodyJ Y Wong, G E Thomas, D Yamauchi, et al.
Bioconjugate Chemistry|March 15, 2011
Site-specific conjugation of monodispersed DOTA-PEGn to a thiolated diabody reveals the effect of increasing peg size on kidney clearance and tumor uptake with improved 64-copper PET imagingLin Li, Desiree Crow, Fabio Turatti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 7, 2004
Pilot trial evaluating an 123I-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancerJeffrey Y C Wong, David Z Chu, Lawrence E Williams, et al.
Cancer Research|July 5, 2005
Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imagingTove Olafsen, Vania E Kenanova, Gobalakrishnan Sundaresan, et al.
European Journal of Nuclear Medicine|August 22, 2000
Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphomaG A Wiseman, C A White, M Stabin, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 6, 2000
High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragmentA M Wu, P J Yazaki, S w Tsai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2003
A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancerJeffrey Y C Wong, Stephen Shibata, Lawrence E Williams, et al.
Cancer Research|February 8, 2005
Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragmentsVania Kenanova, Tove Olafsen, Desiree M Crow, et al.
Pageof 9